Clinical and Therapeutic Implications of Aeromonas Bacteremia: 14 Years Nation-Wide Experiences in Korea
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: To elucidate the clinical presentation, antimicrobial susceptibility, and prognostic factors of monomicrobial Aeromonas bacteremia in order to determine the most effective optimal therapy. Materials and Methods: We reviewed the medical records of Aeromonas bacteremia patients for the period January 2000 to December 2013 in a retrospective multi-center study. Results: A total of 336 patient records were reviewed, with 242 having community-acquired bacteremia. The major clinical infections were of the hepatobiliary tract (50.6%) and peritonitis (18.5%), followed by primary bacteremia (17.9%). The infections usually occurred in patients with malignancy (42.3%), hepatic cirrhosis (39.3%), or diabetes mellitus (25.6%). High antimicrobial- resistance rates (15.5% for ceftriaxone, 15.5% for piperacillin/tazobactam) were noted. However, resistance to carbapenem and amikacin was only 9.8% and 3.0%, respectively. Aeromonas hydrophila (58.9%) was the most common pathogen, followed by Aeromonas caviae (30.4%). The severity of A. caviae bacteremia cases were less than that of A. hydrophila or Aeromonas veronii bacteremia (P <0.05). A. hydrophila showed higher antimicrobial resistance than did other Aeromonas species (P <0.05). Patients with hospital-acquired bacteremia were more likely to have severely abnormal laboratory findings and relatively high antimicrobial-resistance rates. Mortality was associated with metastatic cancer, shock, delayed use of appropriate antimicrobial agents, increased prothrombin time, and increased creatinine level (P <0.05). Conclusions: Aeromonas species should be considered one of the causative agents of bacteremia in patients with intra-abdominal infections or malignancies. Although ceftriaxone-resistant Aeromonas bacteremia was not statistically related to mortality in this study, it was associated with severe clinical manifestations and laboratory abnormalities. Appropriate antibiotics, including carbapenem, should be administered early, especially in Aeromonas bacteremia patients with shock and impaired renal function.
Abstract
Background: To elucidate the clinical presentation, antimicrobial susceptibility, and prognostic factors of monomicrobial Aeromonas bacteremia in order to determine the most effective optimal therapy. Materials and Methods: We reviewed the medical records of Aeromonas bacteremia patients for the period January 2000 to December 2013 in a retrospective multi-center study. Results: A total of 336 patient records were reviewed, with 242 having community-acquired bacteremia. The major clinical infections were of the hepatobiliary tract (50.6%) and peritonitis (18.5%), followed by primary bacteremia (17.9%). The infections usually occurred in patients with malignancy (42.3%), hepatic cirrhosis (39.3%), or diabetes mellitus (25.6%). High antimicrobial- resistance rates (15.5% for ceftriaxone, 15.5% for piperacillin/tazobactam) were noted. However, resistance to carbapenem and amikacin was only 9.8% and 3.0%, respectively. Aeromonas hydrophila (58.9%) was the most common pathogen, followed by Aeromonas caviae (30.4%). The severity of A. caviae bacteremia cases were less than that of A. hydrophila or Aeromonas veronii bacteremia (P <0.05). A. hydrophila showed higher antimicrobial resistance than did other Aeromonas species (P <0.05). Patients with hospital-acquired bacteremia were more likely to have severely abnormal laboratory findings and relatively high antimicrobial-resistance rates. Mortality was associated with metastatic cancer, shock, delayed use of appropriate antimicrobial agents, increased prothrombin time, and increased creatinine level (P <0.05). Conclusions: Aeromonas species should be considered one of the causative agents of bacteremia in patients with intra-abdominal infections or malignancies. Although ceftriaxone-resistant Aeromonas bacteremia was not statistically related to mortality in this study, it was associated with severe clinical manifestations and laboratory abnormalities. Appropriate antibiotics, including carbapenem, should be administered early, especially in Aeromonas bacteremia patients with shock and impaired renal function.
참고문헌 (26)
- Tsai MS, "Clinical features and risk factors for mortality in Aeromonas bacteremic adults with hematologic malignancies", J Microbiol Immunol Infect, 39, pp.150~154 (2006)
- Wu CJ, "Clinical significance and distribution of putative virulence markers of 116 consecutive clinical Aeromonas isolates in southern Taiwan", J Infect, 54, pp.151~158 (2007)
- Lee WS, "Retrospective study of Aeromonas infection in a Malaysian urban area: a 10-year experience", Singapore Med J, 42, pp.57~60 (2001)
- Mandell GL, "Mandell, Douglas and Bettett's Principles and practice of infectious diseases" (2005), Elsevier Churchill Livingstone
- Llopis F, "Epidemiological and clinical characteristics of bacteraemia caused by Aeromonas spp. as compared with Escherichia coli and Pseudomonas aeruginosa", Scand J Infect Dis, 36, pp.335~341 (2004)
- Ko WC, "Inducible beta-lactam resistance in Aeromonas hydrophila: therapeutic challenge for antimicrobial therapy", J Clin Microbiol, 36, pp.3188~3192 (1998)
- Ko WC, "Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia", J Infect, 40, pp.267~273 (2000)
- Choi JP, "Clinical significance of spontaneous Aeromonas bacterial peritonitis in cirrhotic patients: a matched case-control study", Clin Infect Dis, 47, pp.66~72 (2008)
- Rhee JY, "Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the acute physiology and chronic health evaluation II scoring systems", Shock, 31, pp.146~150 (2009)
- Clinical and Laboratory StandardsInstitute, "Performance Standards for Antimicrobial Susceptibility Testing:Fifteenth informational supplement", CLSI;M100-S11, ~ (2005)
- Campo C, "Aeromonas spp bacteremia: study of 12 cases and review of the literature", Enferm Infecc Microbiol Clin, 19, pp.161~164 (2001)
- Ko WC, "Aeromonas bacteremia: review of 59episodes", Clin Infect Dis, 20, pp.1298~1304 (1995)
- Lai CC, "Aeromonas hydrophila and Aeromonas sobria bacteremia: rare pathogens of infection in a burn patient", Burns, 33, pp.255~257 (2007)
- Lau SM, "Outcomes of Aeromonas bacteremia in patients with different types of underlying disease", J Microbiol Immunol Infect, 33, pp.241~247 (2000)
- Doudier B, "Aeromonas septicaemia: an uncommon complication following placement of transhepatic biliary drainage devices in Europe", J Hosp Infect, 62, pp.115~116 (2006)
- Huang LJ, "Secondary Aeromonas peritonitis is associated with polymicrobial ascites culture and absence of liver cirrhosis compared to primary Aeromonas peritonitis", APMIS, 114, pp.772~778 (2006)
- Sebo P, "Aeromonas bacteremia in an elderly immunocompetent patient", Aging Clin Exp Res, 18, pp.344~346 (2006)
- Sánchez-Céspedes J, "Development of imipenem resistance in an Aeromonas veronii biovar sobria clinical isolate recovered from a patient with cholangitis", J Med Microbiol, 58, pp.451~455 (2009)
- García-Irure JJ, "Spontaneous bacterial peritonitis and bacteraemia due to Aeromonas hydrophila", An Sist Sanit Navar, 26, pp.429~431 (2003)
- Funada H, "Aeromonas bacteremia in patients with hematologic diseases", Intern Med, 36, pp.171~174 (1997)
- Harris RL, "Bacteremia caused by Aeromonas species in hospitalized cancer patients", Rev Infect Dis, 7, pp.314~321 (1985)
- Kimura M, "Aeromoans caviae is the most frequent pathogen among cases of Aeromonas bacteremia in Japan", Scand J Infect Dis, 45, pp.304~309 (2013)
- Kao HT, "Fatal bacteremic pneumonia caused by Aeromonas hydrophila in a previously healthy child", J Microbiol Immunol Infect, 36, pp.209~211 (2003)
- Tang HJ, "Clinical manifestations of bacteremia caused by Aeromonas species in southern Taiwan", PLoS One, 9, pp.e91642~ (2014)
- Tena D, "Extraintestinal infection due to Aeromonas spp.: review of 38 cases", Enferm Infecc Microbiol Clin, 25, pp.235~241 (2007)
- 김지은, "Anaerobic Bacteremia: Impact of Inappropriate Therapy on Mortality", Infection and Chemotherapy, 48(2), pp.91~98 (2016), 대한감염학회